FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 110 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Patients With DCIS Reduce Risk Of Recurrence And Death If They... June 25, 2020 ESMO Breast Cancer Congress 2022 April 20, 2022 How to Safely Keep Up With Your Cancer Screening and Care... December 10, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab October 29, 2021 Load more HOT NEWS FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC What’s at the Root of Ovarian Cancer? New Study May Have... Touching a nerve: How neuroscience could advance our understanding of cancer Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma
